Subject category:
Strategy and General Management
Published in:
2000
Length: 29 pages
Data source: Field research
Share a link:
https://casecent.re/p/22246
Write a review
|
No reviews for this item
This product has not been used yet
Abstract
This is the second of a two-case series (300-101-1 and 300-102-1). On 31 March 1995 BASF AG acquired Boots Pharmaceuticals from Boots PLC for DM2bn (£850m) + $70m (£44m). The deal represented the culmination of the strategic goal of BASF, one of the world''s largest chemical companies, and its pharmaceutical subsidiary Knoll AG, to grow by acquisition and organically in the rapidly changing industry. Part One of the case looks at the pharmaceutical industry in 1994, and the strategic alternatives open to Knoll. Part Two looks at integration planning and implementation. A video is available to accompany the case series (300-101-3).
About
Abstract
This is the second of a two-case series (300-101-1 and 300-102-1). On 31 March 1995 BASF AG acquired Boots Pharmaceuticals from Boots PLC for DM2bn (£850m) + $70m (£44m). The deal represented the culmination of the strategic goal of BASF, one of the world''s largest chemical companies, and its pharmaceutical subsidiary Knoll AG, to grow by acquisition and organically in the rapidly changing industry. Part One of the case looks at the pharmaceutical industry in 1994, and the strategic alternatives open to Knoll. Part Two looks at integration planning and implementation. A video is available to accompany the case series (300-101-3).